Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	ACR
Latest Price:	3.55 (2.60% )
52-week High:	4.24
52-week Low:	2.71
Market Cap:	591.06M

1 year chart

1 day chart

Acrux Limited

Acrux is a dynamic Australian drug delivery business developing and commercialising a range of patient-preferred pharmaceutical products for global markets, using patented technology to administer drugs through the skin.

Acrux cracks global licensing deal with Eli Lilly

Tuesday, March 16, 2010

Australian drug developer Acrux (ASX:ACR) has inked an exclusive global licensing deal with pharmaceutical giant Eli Lilly for the commercialisation of AXIRON, to treat testosterone deficiency in men.

The company said this would progress Acrux to become the first Australian biotech company to introduce a number of therapeutic products into global pharmaceutical markets.

Under the terms of the AXIRON deal, Acrux is eligible to receive up to US$335 million in milestone payments, plus royalties on worldwide sales.

Acrux uses its innovative technology to administer drugs through the skin.

Acrux has forecast a maiden profit after tax for 2009/10 between $44 million and $48 million. With dividend payments to commence in 2011, subject to FDA approval of AXIRON.

Acrux was founded as a spin-off from Monash University a decade ago.

Eli Lilly has worldwide sales of its erectile dysfunction treatment Cialis® of US$1.6 billion in 2009, now rivalling Pfizer’s Viagra® as the largest selling product in this category.

Acrux believes that Lilly has the expertise and capabilities in men’s health that will enable Acrux to achieve the full commercial potential of AXIRON.

From the initial payment of US$50 million, third-party royalties of approximately A$1.9 million are expected to be payable.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.